Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 13/20 | 0.39 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23023554 | 0.84 | CBLB (0.45) | NPSR1PDE2AMLYCDHDAC4 | |
| SCHEMBL22550925 | 0.83 | HDAC4 (0.37) | PDE2ACYP3A4CYP2D6TSHRCRHBP | |
| SCHEMBL22540948 | 0.80 | CYP3A4 (0.38) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL6120983 | 0.77 | CYP1A2 (0.43) | NPSR1MLYCDKDM4EALDH1A1HPGD | |
| SCHEMBL18068094 | 0.75 | CYP3A4 (0.50) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL22924538 | 0.75 | CBLB (0.45) | NPSR1MLYCDCYP3A4HDAC4KDM4E | |
| SCHEMBL22550861 | 0.73 | NPSR1 (0.44) | NPSR1PDE2AMLYCDCYP3A4CYP2D6 | |
| SCHEMBL22550831 | 0.72 | PDE2A (0.42) | PDE2ATSHR | |
| SCHEMBL22540918 | 0.72 | NPSR1 (0.46) | NPSR1PDE2AMLYCDHDAC4KDM4E | |
| SCHEMBL24028582 | 0.70 | NPSR1 (0.43) | NPSR1PDE2AMLYCDTSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355599-A1 | BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE | NURIX THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230355599-A1 | BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE | NURIX THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230212186-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | NURIX THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212186-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | NURIX THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230150991-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150991-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-11530229-B2 | Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof | NURIX THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210053986-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | NURIX THERAPEUTICS, INC. | 2021-02-25 | — | — | US | disclosed |
| US-20210053961-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. | 2021-02-25 | — | — | US | disclosed |
| US-20200323904-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS | NURIX THERAPEUTICS, INC. | 2020-10-15 | — | — | US | disclosed |
| WO-2020210508-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS | NURIX THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053986-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | CBLB, CBL, CBLC | NPSR1 4801/4885PDE2A 4241/4885MLYCD 928/4885 |
| US-20230150991-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | CBL, CBLB, CBLC | NPSR1 4823/4885PDE2A 4333/4885MLYCD 1830/4885 |
| US-20230355599-A1 | BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE | CBL, CBLB, CBLC | NPSR1 4483/4885PDE2A 4622/4885MLYCD 3230/4885 |
| US-11530229-B2 | Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof | CBLB, CBL, CBLC | NPSR1 4801/4885PDE2A 4241/4885MLYCD 928/4885 |
| US-20210053961-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | CBL, CBLB, CBLC | NPSR1 4823/4885PDE2A 4333/4885MLYCD 1830/4885 |
| US-20230212186-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | CBLB, CBL, CBLC | NPSR1 4801/4885PDE2A 4241/4885MLYCD 928/4885 |
| US-20200323904-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS | CBLB, CBL, CBLC | NPSR1 4739/4885PDE2A 3801/4885MLYCD 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.